Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03059485 | DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | active not recruiting | Phase 2 | 82 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03597321 | Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML(ELIT-AML01) | active not recruiting | Phase 2 | 124 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT02392429 | FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT02782546 | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | active not recruiting | Phase 2 | 60 | Washington University School of MedicineOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06379360 | Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients | active not recruiting | Phase 2 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06668558 | Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia(VERDI) | active not recruiting | Phase 2 | 28 | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04657081 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | active not recruiting | Phase 1 / Phase 2 | 101 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 16, 2026 | clinicaltrials |
| NCT03849651 | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies | active not recruiting | Phase 2 | 69 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 70 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03953898 | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06429098 | Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML | active not recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04746235 | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 85 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04262843 | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia | active not recruiting | Phase 2 | 33 | City of Hope Medical CenterOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01885689 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 72 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07163793 | Pilot Study of Reduced Venetoclax Exposure | active not recruiting | Phase 2 | 41 | Northwell HealthOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06232655 | Cladribine Venetoclax in Monocytic AML | active not recruiting | Phase 2 | 10 | University of Colorado, DenverOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07779031 | A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT(TP53) | active not recruiting | Phase 1 / Phase 2 | 58 | Liping DouOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02835222 | Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | active not recruiting | Phase 2 | 57 | Wake Forest University Health SciencesOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05796570 | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies(MORE) | active not recruiting | Phase 2 | 29 | Franziska WachterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03503409 | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | active not recruiting | Phase 2 | 68 | Groupe Francophone des MyelodysplasiesOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2026 | clinicaltrials |
| NCT02861417 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 204 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06456463 | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy(TRILLIUM) | active not recruiting | Phase 2 | 85 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04975919 | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02506933 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | active not recruiting | Phase 2 | 102 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | active not recruiting | Phase 2 | 30 | University of California, IrvineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02935361 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | active not recruiting | Phase 1 / Phase 2 | 33 | University of Southern CaliforniaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 133 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02094794 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | active not recruiting | Phase 2 | 108 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03289910 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04668885 | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | active not recruiting | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | May 28, 2026 | clinicaltrials |
| NCT03747757 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | active not recruiting | Phase 2 | 41 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials